Cytomegalovirus infection among patients with cancer receiving immune checkpoint inhibitors.

ABSTRACT:

Background

Immune checkpoint inhibitors (ICIs), used for the treatment of solid and hematologic malignancies, come with the risk of immune-related adverse events (irAEs). Opportunistic infections (e.g., cytomegalovirus [CMV]) mimic irAE symptoms and are understudied in this population. We aimed to describe the incidence, characteristics, treatment and outcomes of CMV infection in ICI-treated patients.

Methods

We conducted a single-center retrospective review of all adult patients who were CMV-positive after ICI therapy between 06/2011 and 05/2020. A CMV-positive non-ICI cohort was matched to the ICI group based on age, sex and cancer type. Variables of interest were collected through electronic medical records.

Results

The study population comprised 192 patients overa

SUBMITTER: Panneerselvam K 

PROVIDER: S-EPMC9399572 | biostudies-literature | 2022 Sep-Oct

REPOSITORIES: biostudies-literature